NCT05753722 - A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies | Biotech Hunter

Enrollment

270

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions

Advanced or Metastatic Solid Tumors

Interventions

BIOLOGICAL

PRTH-101

PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

BIOLOGICAL

Pembrolizumab

PRTH-101 in combination with Pembrolizumab

Trial Locations (9)

COMPLETED

University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh

RECRUITING

Next Oncology, Fairfax

RECRUITING

Vanderbilt-Ingram Cancer Center, Nashville

RECRUITING

Next Oncology, Irving

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

RECRUITING

NEXT Oncology, San Antonio

RECRUITING

Providence Cancer Institute Franz Clinic, Portland

RECRUITING

Yale Cancer Center, New Haven

RECRUITING

Mass General Cancer Center, Boston